ABSTRACT
INTRODUCTION
There is an epidemic of vitamin D deficiency, with over one billion people worldwide affected [1] . 
VITAMIN D AND THE VITAMIN D RECEPTOR
Vitamin D is a lipid-soluble, secosteroid hormone which is primarily associated with calcium homeostasis [3] . Synthesis of vitamin D occurs predominantly in the skin from dehydrocholesterol, the shared common precursor with cholesterol, and is dependent on sun exposure [4] . Ultraviolet B light of wavelengths between 280 and 315 nm is optimal for the conversion of 7-dehydrocholesterol to previtamin D 3 , which is then converted to vitamin D 3 in the skin.
During summer, exposure to midday sunlight for 20-30 min, two or three times per week is thought to be sufficient in generating adequate levels of vitamin D for a fair-skinned individual [5] . (\25 nmol/l) as severely deficient [3] . The US Institute of Medicine (IoM) released guidance in 2011 in which 25(OH)D equal to 20 ng/mL was considered to be adequate for C97.5% of the population [6] ; however, this has been heavily criticized by the Endocrine Society [7, 8] and [10] .
Vitamin D insufficiency which is not low enough to cause bone disease is significantly associated with cardiovascular disease [11] .
There is a ubiquitous expression of vitamin D receptors (VDR) in virtually every human tissue, and vitamin D is an important regulator of literally hundreds of genes regulating key biological processes from cell division to apoptosis [11] .
VDR is widely distributed in many tissues [12] , which suggests a putative biological response with its activation, implying that VDR has multiple functions beyond calcium homeostasis [12] . Once [16] . A cross-sectional study by Dobnig et al. [17] found an inverse relationship between lower levels of vitamin D [26, 27] . RAAS plays a pivotal role in maintaining sodium and blood volume homeostasis by modulating renal function and blood pressure [28] . Upregulation of RAAS leads to the development of hypertension and increased cardiovascular risk [28] [26, 27] . Vitamin D is a potent negative regulator of the RAAS system, which may play an important role in the development of neuropathy in diabetes. RAAS inhibition is one of the few proven therapies, which may prevent or delay diabetic peripheral neuropathy (DPN), evidenced by experimental studies but also two human clinical trials [29] [30] [31] . In an experimental model of type 1 diabetes mellitus, plasma renin activity levels were decreased whereas ACE activity was increased in diabetic rats compared with controls [31] . A small open-label study of lisinopril in hypertensive subjects (n = 13) showed improvements in nerve conduction measures over 12 weeks [29] and a double-blind randomized controlled study found that administration of the ACE concentration \20 ng/mL had a higher cumulative incidence of macrovascular and microvascular events than those with levels C20 ng/mL [46] . Indeed severe vitamin D deficiency has been shown to predict not only mortality but the development of nephropathy and retinopathy in type 1 diabetes [47] . [57] ; however, further larger interventional studies are required to truly assess any therapeutic benefit [58] .
VITAMIN D, NERVES, AND DIABETIC NEUROPATHY
Nerve growth factor (NGF) was first identified as being essential for the development of nociceptive primary neurons and later found to have a role in inflammatory hyperalgesia in adults [59] . NGF is a neurotrophic factor which is synthesized initially as pro-NGF, prior to being cleaved by intracellular proteases before being translocated to the rough endoplasmic reticulum and is cleaved a second time by extracellular proteases to produce the active form [59] . NGF is responsible for the development and maintenance of neurons in several regions in the central nervous system [59, 60] Importantly, topical application of NGF in diabetic foot ulcers has resulted in promotion of healing [76] . NGF has previously been successfully studied in phase 2 clinical trials [77] but showed a lack of efficacy in a phase 3 study for DPN [78] . [83] . Other studies have assessed ethnic differences in DPN in a US population with variations noted in risk for DPN and diabetic autonomic neuropathy [84] . However, in an Australian study there were no significant differences between ethnic groups [85] although the ethnic mix of the last two studies differs from that in the UK.
An increasing body of data suggests that vitamin D may have not only analgesic properties but also additional neuroprotective benefits. Vitamin D deficiency and insufficiency are associated with various pain syndromes and low levels of vitamin D correlated with the presence of peripheral neuropathy in primary Sjögren's syndrome which can lead to a small fiber neuropathy [86] . Vitamin D supplementation has been shown to improve musculoskeletal pain and non-traumatic back pain in some studies [87] . However, there is a prominent contrast in treatment effects between randomized, double-blind trials that minimized bias and those with designs known to be subject to bias [87] with better treatment effects noted in the latter. Therefore, the overall evidence for the use of vitamin D for chronic pain in adults is poor because of low-quality and insufficient RCTs [87] . [92] . Large nerve fiber deficits have also been associated with vitamin D status in diabetes mellitus [93] . In an age, sex, body mass index (BMI), height, and disease duration matched cohort (n = 33) of patients with diabetes, 25(OH)D was significantly lower in the DPN group (21.2 ± 11.5 vs. 13.5 ± 5.1 ng/ mL, P = 0.001) [93] . After further adjustment for all studied variables, serum vitamin D had an independent and inverse association with both DPN presence and severity, as each 1 ng/mL increase in serum 25(OH)D was correlated with 2.2% and 3.4% decrease in the presence and severity of nerve conduction studies (NCV) impairment, respectively [93] .
In a meta-analysis of six studies that involved a total of 1484 patients with type 2 diabetes, vitamin D deficiency (\20 ng/mL) was significantly associated with an increased risk of DPN [94] . The OR was 2.88 (95% CI, Scale (pain) [98] . Although the placebo effect can be considerable in trials of therapeutic agents in painful DPN, the maximal placebo effect expected would be no more than approximately 30% [99] . Indeed a 50% pain reduction is considered to be efficacious when evaluating interventions in painful DPN [99] .
Valensi et al. [100] conducted a double-blind RCT of a compound (QR-333) containing a vitamin D analogue and showed positive effects on numbness, jolting pain, and irritation in subjects with painful DPN. However, the outcomes of this study are somewhat confounded as QR-333 contained quercetin, a flavonoid with aldose reductase inhibitor effects, which is one of the key pathogenetic pathways causing diabetic neuropathy.
One of the key 'hard endpoints' of DPN is foot ulceration, which may eventually lead to lower limb amputation and significant morbidity and mortality [101] . In a cross-sectional study of diabetic patients without (n = 162) and with (n = 162) plantar ulcers, lower 25(OH)D status was associated with plantar ulceration in patients with diabetes (6.3 vs. 28 ng/mL, P\0.005) [102] . In a further study by Tiwari et al. [103] , vitamin D deficiency was more prevalent and severe in patients with diabetic foot infection. Cases of foot infection (n = 125) had a greater risk of vitamin D deficiency (25(OH)D \20 ng/mL) than controls (n = 164) with an OR of 1.8 (95% CI, 1.1-3.0; P = 0.02) and the risk of severe vitamin D deficiency (25(OH)D \10 ng/ mL) was significantly higher in cases than in controls with an OR of 4.0 (95% CI, 2.4-6.9; P\0.0001) [103] .
VITAMIN D AND DIABETIC NEPHROPATHY
Considerable data exist on the role of vitamin D in diabetic nephropathy [104] . Patients with chronic kidney disease (CKD) are known to have deficiency of both 25(OH)D and 1,25(OH) 2 D, which is associated with a high cardiovascular mortality. These risks can be partially ameliorated by treatment with vitamin D analogues [105] . Although in patients with CKD, higher levels of vitamin D may also be associated with vascular calcification [106] . Experimental studies have shown a role of the VDR, and VDR-mediated vitamin D actions are thought to be renoprotective in diabetic nephropathy [107] . In an experimental study, vitamin D/VDR signaling in podocytes played a critical role in the protection of the kidney from diabetic injury [108] . Analysis of the NHAHES (2001-2006) cross-sectional data showed that there was an independent association between vitamin D deficiency and insufficiency with the presence of nephropathy [109] . In a small double-blind, randomized placebo-controlled, crossover trial of paracalcitriol (a vitamin D analogue) in patients with proteinuria despite adequate RAAS blockade, the urinary albumin excretion rate was significantly further lowered compared to placebo [110] . Furthermore, combination therapy with an AT1 blocker and a vitamin D analogue markedly ameliorated diabetic nephropathy in an experimental model of diabetic nephropathy [111] . In the VITAL study (ClinicalTrials.gov identifier, NCT00421733), a placebo-controlled, double-blind RCT, paracalcitriol (a vitamin D analogue) added to RAAS inhibition at a dose of 2 lg/day significantly lowered blood pressure and residual albuminuria in patients with diabetic nephropathy [112] , further highlighting the role of vitamin D as a potent RAAS inhibitor [113, 114] . Recently, a systematic review and meta-analysis by Derakhshanian et al. [115] suggested that despite a higher risk for nephropathy in vitamin D-deficient patients with diabetes, vitamin D supplementation did not support causality in this association. A pooled data of urinary albumin-creatinine ratio levels in clinical trials (five trials, n = 219) suggested no significant change following vitamin D supplementation [115] . However, these studies were small and heterogeneous and the vitamin D replacement dose was small. Thus, larger well-designed RCTs with adequate vitamin D supplementation in diabetic nephropathy are required.
VITAMIN D AND DIABETIC RETINOPATHY
25(OH)D concentrations are associated with optic chiasm volume [116] and several studies have found an association between vitamin D deficiency and age-related macular degeneration (AMD) [117, 118] . In a mouse model of ischemic retinopathy, 1,25(OH) 2 D was
shown to inhibit neovascularization in retinal tissue [119] . In a Turkish cohort of 66 subjects, 
